Canada markets open in 1 hour 44 minutes

Primo Nutraceuticals Inc. (PRMO.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.12000.0000 (0.00%)
At close: 3:48PM EDT
Full screen
Previous Close0.1200
Open0.0000
Bid0.1100 x N/A
Ask0.1300 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume70,839
Market Cap1.211M
Beta (5Y Monthly)0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.7120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Marianna Naturals Corp. Appoints Integral Transfer Agency as its Transfer Agent, and Secures Its CUSIP & ISIN
    GlobeNewswire

    Marianna Naturals Corp. Appoints Integral Transfer Agency as its Transfer Agent, and Secures Its CUSIP & ISIN

    MONTREAL, Oct. 26, 2020 (GLOBE NEWSWIRE) -- (MARIANNA NATURALS CORP.) is pleased to announce that it has retained the services of Integral Transfer Agency as its transfer agent and share registrar. The company signed the agreement with Integral on October 16th, 2020. This is an important move for the company in its final steps to list its common shares on the CSE via Statutory Plan of Arrangement with its partner company Primo Nutraceuticals Inc. (C:PRMO) Marianna Naturals signed a definitive Capital Market Advisory Agreement with Primo on April 29th, 2020 with the company agreeing to assist Marianna in becoming a “reporting issuer” while helping with business development, strategic management, and organizational services. Pertinent information related to that agreement can be seen in Primo’s corporate press release dated May 4th, 2020.Over the course of the last few weeks the company has been extremely busy in preparing all the necessary paperwork and financials required of them by Primo and their audit committee. The management team at Marianna Naturals is keen on listing its shares on the CSE; and is anticipating swift approval in the very near future.The company is aware that court order of approval is required by the British-Columbia Supreme Court as well as approval that is seemingly imminent, at a “shareholder special meeting” to be held by Primo in the coming weeks.The management team at Marianna would also like to announce that they have received both their CUSIP & ISIN numbers respectively by the Canadian Depository for Securities (CDS). Both numbers were issued to the company on October 8th, 2020. CUSIP 56671R1001 & ISIN CA56671R1001 uniquely identify Canadian or American securities.Marianna Naturals Corp. is pleased to welcome Sheryl Dhillon to the Board of Directors, having recently been appointed as Corporate Secretary. Sheryl brings a wealth of knowledge and expertise to the board serving in several Corporate Secretary positions for numerous public companies over the course of the last 15 years.Joel DeBellefeuille, Director & CEO of Marianna Naturals Corp. Comments: “We are now moving forward at a quicker pace with the listing of Marianna Naturals Corp.’s common shares on the CSE; imminent. We are extremely pleased with the professionalism of the team at Primo and look forward to seeing the company stock trading on the CSE very soon.”About Integral Transfer Agency Integral is a recognized transfer agency with CDS Clearing and Depository Services Ltd., Canada’s stock clearing agency.  Integral Transfer Agency prides themselves on being independent, impartial and accurate; delivering exceptional service to their stakeholders using an integrative approach, which ensures continual improvement and innovation.About Sheryl Dhillon  Ms. Dhillon is a highly experienced corporate secretary with over fifteen years of experience. She has extensive knowledge of corporate governance, as well as strong management skills and excellent corporate communications. Ms. Dhillon acts as Corporate Secretary for several TSXV and CSE listed companies. About Marianna Naturals Corp. Marianna Naturals Corp. and Beauty Kitchen manufactures fresh handmade CBD & non-CBD beauty care, personal care, and cosmetics products, which was born from the hugely popular Beauty Kitchen YouTube series. The founder, Heather Marianna, a bubbly social media personality, translated her passion for looking and feeling her absolute best into the development of her all-natural beauty and skincare product line. Beauty Kitchen’s founder and CEO, Heather Marianna, skyrocketed in popularity with the launch of her Beauty Kitchen YouTube series in 2012 where she showcased simple, do-it-yourself beauty recipes made with common kitchen household ingredients. The series generated a powerful following of more than 4 million viewers. Beauty Kitchen is regularly featured in: Forbes, The Source, MTV, Bravo, The New York Post, People, Flipsnack, Vegas, Star Magazine, Radar Online and many more media outlets with a large following of celebrities who use their products. For more information visit: www.mariannacorp.comContactsJoel DeBellefeuille, Chief Executive Officer, Director E. joel@marianna.ca Tel. 514-434-2640 For media inquiries: press@mariannacorp.comShop: www.marianna.caFORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

  • Primo Nutraceuticals Inc. signs a Memorandum of Understanding for Exclusive Rights to Sell Rapid (Colloidal Gold Method) COVID-19 Test Kits in Canada
    GlobeNewswire

    Primo Nutraceuticals Inc. signs a Memorandum of Understanding for Exclusive Rights to Sell Rapid (Colloidal Gold Method) COVID-19 Test Kits in Canada

    COVID-19 Test Kits COVID-19 Test KitsVANCOUVER, British Columbia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF ) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (" PRIMO " or the "Company") announces the signing of a Memorandum of Understanding (MOU) with Neo-Nostics ™ (Suzhou) Bioengineering Co. Ltd. Of Su Zhou City, China (“Neo-Nostics”) as the official trade representative for Neo-Nostics ™ with the exclusive rights to apply for licensing and to market and sell the following COVID-19 production Canada: Neo-Nostics ™ 2019-nCoV IgG/IgM Rapid Test Kit (Colloidal Gold Method) (Test Kit). The Memorandum of Understanding between Primo and Neo-Nostics ™, is effective as of October 13, 2020. Upon successfully receiving product license and approval by Health Canada, Neo-Nostics ™ will grant Primo with “Official Dealer/Distributor Status” in Canada.The Neo-Nostics ™ 2019-nCoV IgG/IgM Rapid Testing Kit is currently registered with the FDA. Primo will be submitting the application for approval to Health Canada immediately. Neo-Nostics ™ has committed to supporting Primo's efforts to obtain and maintain all necessary certifications and approvals for the sale and marketing of the Test Kits in Canada by granting access to all necessary documentation and clinical studies concerning the Test Kits.Follow the link for a video demonstration: http://www.neo-nostics.com/skin/images/mp40.mp4About the Neo-Nostics ™ Rapid Test KitsThe Neo-Nostics ™ 2019-nCoV Antibody Detection Reagent Kit (Colloidal Gold Method) has the advantage of rapidity, convenience, high accuracy, and can make up for the shortcomings of professional requirements, time consumption and low positive detection rate of PCR nucleic acid detection, and can be used as an important supplementary detection method for the diagnosis of coronal pneumonia.Through detection and calculation, it is found that the comprehensive accuracy rate of the Neo-Nostics ™ 2019-nCoV IgM Detection Reagent is higher than 95%.During the worst period of the epidemic in China, the reagent kit was donated to hospitals and the CDC in the most severely infected areas of Hubei for clinical auxiliary diagnosis. At present, the verification reports made by three clinical units prove that the positive detection rate of clinically confirmed cases has reached 92%, which has exceeded the general detection effect. Not only negative or positive results can be detected, but also the early, middle and or recovery period of virus infection can be distinguished by the positive strength of IgM or IgG. Source: Clinical study report conducted by the Institute of Virology, in the capital city of Hubei, China and The Chinese Academy of Sciences in Beijing, China.DISCLAIMER: "The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time".Clinical Applications of ReagentsThis reagent has been used by professionals in China since February 2020 in an area that was the hardest hit and impacted most severely by COVID-19, in the form of clinical auxiliary diagnosis.The reagent kit was clinically verified by several professionals, hospitals, and universities respectively, and corresponding reports were used as reference.At present, Iran, Italy, the United States, and other red zones have already adopted it. Neo-Nostics™ has CE declaration of conformity, local records of European Authorized Representative and FDA records in the United States.View the FDA records here: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm?lid=669386&lpcd=QKOAdvantages of the Colloidal Gold Method1\. Quick - 10 minute results.2\. Simple - The detection results can be determined by the naked eye.3\. Sampling - Only fingertip blood or venous blood is required for detection.4\. It is suitable for clinical auxiliary diagnosis.About the COVID-19 Detection Kit MarketAccording to a new report by Grand View Research, Inc., The global COVID-19 detection kits market size is projected to reach USD 4.63 billion by 2027. The COVID-19 pandemic has posed several challenges to the global healthcare systems. As a result, companies are ramping up their production process to meet the demand or kits and reagents as well as at-home tests, thereby driving the market revenue. https://www.grandviewresearch.com/industry-analysis/covid-19-detection-kits-market?utm_source=prnewswire&utm_medium=referral&utm_campaign=hc_15-sep-20&utm_term=covid-19-detection-kits-market&utm_content=rdMr. Joey Zhou, CEO of Neo-Nostics™ (Suzhou) Bio-Engineering Co. Ltd. Comments:“Penetrating the Canadian market with our advanced and highly effective test kit will be a great milestone for our company as well as for the fight against theCOVID-19 virus. We are pleased to be partnering with Primo Nutraceuticals and their team”Richard Cindric, CEO of Primo Comments:“We are looking forward to working with Neo-Nostics™ to provide a premium quality product. We anticipate the relationship to grow and look forward to updating our shareholders with our future milestones.” It is important to note that receiving the MDEL license from Health Canada has opened up a plethora of opportunities like this one which will result in revenue in the immediate short term for Primo and its shareholders.”About Neo-Nostics™ (Suzhou) Bioengineering Co. Ltd.Neo-Nostics ™ (Suzhou) Bioengineering Co., Ltd. which was established in 2015, is a professional company specialized in researching, developing, manufacturing, and distributing advanced medical instruments and in-vitro medical diagnostic products. Their products are usually used for fertility tests, infectious diseases tests, drugs of abuse tests, alcohol saliva tests, urinalysis reagent strips, cardiac marker tests, tumor marker tests, food and safety tests and animal disease tests.To learn more about Neo-Nostics™ please visit: http://www.neo-nostics.com/en/About Primo Nutraceuticals Inc.Primo Nutraceuticals Inc. ("Primo" or the "Company") is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra's management is in the process of building a corporate road map to further vertically integrate the company; specifically by way of the “Primo” & "Thrive," brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.On behalf of the Board of DirectorsPRIMO NUTRACEUTICALS INC.Andy Jagpal President and DirectorFor further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; info@primoceuticals.com .To learn more about what this news means to the shareholders visit:www.primonutraceuticals.com www.twitter.com/Prmoinc www.thrivecbd.com www.mariannacorp.com www.dcppe.net www.statebelevate.comFORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7edb57dd-f83a-4a28-8829-5baafc9df6c8

  • GlobeNewswire

    Primo Nutraceuticals Inc., Engages MedCan Biotechnologies to Conduct Chemo typing & Geno-typing Studies of Psilocybin Mushrooms

    VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) -- PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) ("PRIMO" or the "Company") Primo Nutraceuticals Inc. has entered intoa non-binding letter of intent (the "LOI") with MedCanBiotechnologies Inc. (“MEDCAN BIOTECH”). MEDCAN BIOTECH will act as a consultant to conduct a chemo typing (Chemical Analysis) and a genotyping (Genetic Analysis) study of up to 5 strains of Psilocybin mushrooms (commonly known as Magic Mushrooms).Terms of EngagementHealth Canada (HC) has recently shifted towards psychedelic-assisted psychotherapies in safe, controlled environments as acceptable treatment options.Pursuant to Section 56 exemption from the Canadian Drugs and Substances Act to treat anxiety associated diagnoses,MEDCAN BIOTECH will apply to Health Canada to receive approval under the Controlled Drug and Substances Act to allow MEDCAN BIOTECH to conduct research in order to effectively standardize the extraction of psilocybin from mushrooms.The Health Canada permitby MEDCAN BIOTECHwill allow to develop and license intellectual property (IP) exclusively for further product development by PRIMO via chemo-typing and geno-typing of 5 different mushrooms to understand their properties.MEDCAN BIOTECHwill proceedto patent methods of analysis and results on behalf of PRIMO, whereby data generated will be used in the production of nutraceutical products.All IPand products developed as a result of the analysis will become the property of PRIMOfor their exclusive use.Psychedelic research focused on psychedelic medicine and psychedelic drugs have demonstrated that these substances have potential for treating ailments including anxiety, addiction, depression, substance dependency, attention deficit hyperactivity disorder and even post-traumatic stress disorder.The data produced can be used to generate premium natural health mushroom nutraceutical products. Genotyping can be used for the identification and labeling of different varieties of psilocybin mushrooms.About MEDCAN BIOTECHMEDCAN BIOTECH is an all-natural solution research and development company to better personal wellbeing.MEDCAN BIOTECH has already researched and formulated a range of cannabinoid products that combine with the multi-faceted cannabinoid component with other natural active ingredients to create products for Sleep, Mood, Mind and Pleasure presented online at: www.medcanbiotech.comFounder, Dr. David Noshad is a part-time faculty member at British Columbia’s Thompson Rivers University as well as President of Bio-Act Technology which specializes in research and development consulting with respects to life-science, cannabis and agri-food industry.In 2010, Dr. Noshad served as Principle Co-Investigator with the UBC’s Faculty of Pharmaceutical Sciences in cannabis pharmacology; characterizing cannabinoids and terpenes in cannabis and Humulus. The projects included in vitro culture techniques, biochemical analysis, molecular biology and genomic techniques.About the Psychedelic MarketIn the first half of 2020, US$150 million was raised by psychedelics-focused companies. The research group projects that the global psychedelics industry may reach a total value of US$7 billion by the year 2027. According to: https://reportonpsychedelics.com/Richard Cindric, CEO of Primo Comments:“It is an honor to have Dr. Noshad collaborating with us. We are confident his qualifications and experience in characterizing cannabinoids and terpenes in cannabis will translate into the development of IP focusing on psilocybin treatments for neuropsychiatric diseases.By investing resources in functional mushroom beverages with Brujera Elixer, as well as developing an IP on psychedelics with MedCan, we will be able to introduce premium natural health mushroom products toboth thepsychedelic and non-psychedelic market places.”About Primo Nutraceuticals Inc.Primo Nutraceuticals Inc. ("Primo" or the "Company") is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra's management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & "Thrive," brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License(MDEL) from Health Canada.On behalf of the Board of DirectorsPRIMO NUTRACEUTICALS INC.“AndyJagpal”Andy Jagpal President and DirectorFor further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; info@primoceuticals.com .To learn more about what this news means to the shareholders visit:www.primonutraceuticals.com www.twitter.com/Prmoinc www.thrivecbd.com www.mariannacorp.com www.dcppe.net www.statebelevate.comFORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.